1. Scrip
  2. >>Business
  3. >>Earnings

Madrigal’s Rezdiffra Continues Its Solid Launch

 
• By Joseph Haas

With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
Madrigal's Rezdiffra continued its early growth through three quarters on the market • Source: Alamy

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted strong year-over-year sales growth for 2025, driven partially by expected EU approval and initial launch in Germany later this year.

Key Takeaways
  • Madrigal continues to beat Wall Street projections for the launch of Rezdiffra, the first approved MASH drug.

The Conshohocken, PA-based company also reported two-year data from a cohort of MASH patients with cirrhosis from an ongoing study,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Regulatory Setbacks Dim Otherwise Strong Quarter For Regeneron

 
• By Alaric DeArment

Eylea HD saw significant sales growth, but the company reported delays in FDA approvals for the drug and a CRL for its CD20xCD3-targeting bispecific for lymphomas.

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By Manas Mishra

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.